Physician profile
David Segal
NPI 1720730419
$6,530.73
in general payments reported to CMS, 2019-2025
23 companies · $3,878 in 2025
The $3,878 reported for 2025 was more than what 81% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $381 · 2023: $580 · 2024: $1,692 · 2025: $3,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Travel and Lodging: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,054.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Travel and Lodging | $594.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,550.24 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Insulet Corporation | $426.50 | 2022-2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $308.19 | 2023-2025 | Skytrofa |
| Sanofi-Aventis U.S. LLC | $281.26 | 2022-2025 | |
| Abbott Laboratories | $120.81 | 2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $104.81 | 2024-2025 | |
| Eton Pharmaceuticals, INC. | $91.13 | 2025 | Increlex, Alkindi, Khindivi |
| Sequel Med Tech, LLC | $85.94 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $82.62 | 2022-2023 | Dupixent |
| Beta Bionics, INC. | $70.11 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $60.41 | 2022-2023 | Gvoke Hypopen |
| Pfizer INC. | $57.35 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $49.63 | 2024-2025 | Triptodur |
| Soleno Therapeutics, INC. | $47.88 | 2025 | Vykat Xr |
| Dexcom, INC. | $45.10 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $27.80 | 2025 | Supprelin |
| Biomarin Pharmaceutical INC. | $22.47 | 2023 | Voxzogo 1.2mg |
| Tolmar Pharmaceuticals, INC. | $20.60 | 2022 | |
| Mannkind Corporation | $18.14 | 2025 | |
| Novo Nordisk INC | $17.57 | 2023 | Sogroya |
| Tolmar, INC. | $15.64 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $13.33 | 2022 | |
| Albireo Pharma, INC. | $13.20 | 2023 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.